ClinicalTrials.gg
CompletedNCT07923994MorphineUpdated Nov 9, 2026

Morphine (10, 20 mg) in a Postoperative Dressing

A Phase 4 interventional study of Morphine Sulfate 10Mg/1mL Injection and Morphine Sulfate 20 MG/ML in Burns, sponsored by Poznan University of Medical Sciences. Completed. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Poznan University of Medical Sciences · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 8 years 2 months after the study started (first participant enrolled Jan 2016, registered Mar 2024).
Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The study will mainly focus on pain management using 10mg or 20mg morphine burn wound dressing at Poznan University of Medical Sciences.

Read the detailed description

Subjects will be randomly assigned to one of the two treatment groups, A and B. Patients scheduled for burn surgery will sign written consent pre-operatively about procedural pain management. Group A will receive 10mg morphine in wound dressing, while those in Group B will receive 20mg morphine in wound dressing.

02

Conditions studied

  • Burns

Browse trials for

Keywords

  • morphine sulfate
  • dressing
  • analgesia
  • pain management
  • burns
03

In context

Burns

905 studies on the registry are indexed under Burns; 164 are open to participants now.

This study's enrollment of 20 is below the median of 40 across 663 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

Poznan University of Medical Sciences is the lead sponsor of 151 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults scheduled for surgical burn treatment
  • aged > 18 years
  • 1,2 or 3

Exclusion criteria

Exclusion Criteria:

  • opioid abuse
  • 4, 5
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Group A (10mg morphine)

    The burn wound was covered with a three-layer sterile dressing. The first layer was a dressing soaked in Octanisept (a solution of octenidine dihydrochloride and phenoxyethanol) with Morphine (Morphine Sulfas WZF), the second dressing with paraffin, and the third dry dressing. Octenisept (Schulke\&Mayer Poland, 1000ml) is a disinfectant liquid. The 1 gram of Octenisept contains 1 mg of octenidine dihydrochloride and 20 mg of Phenoxyethanol. 10mg of Morphine (Morphine Sulfas WZF solution for injection 10mg/ml. Polfa Warsaw) was added to Octenisept in wound dressing.

    Drug: Morphine Sulfate 10Mg/1mL Injection

  • Active comparator
    Group B (20mg morphine)

    The burn wound was covered with a three-layer sterile dressing. The first layer was a dressing soaked in Octanisept (a solution of octenidine dihydrochloride and phenoxyethanol) with Morphine (Morphine Sulfas WZF), the second dressing with paraffin, and the third dry dressing. Octenisept (Schulke\&Mayer Poland, 1000ml) is a disinfectant liquid. The 1 gram of Octenisept contains 1 mg of octenidine dihydrochloride and 20 mg of Phenoxyethanol. 20mg of Morphine (Morphine Sulfas WZF solution for injection 10mg/ml. Polfa Warsaw) was added to Octenisept in wound dressing.

    Drug: Morphine Sulfate 20 MG/ML

Interventions

  • DrugMorphine Sulfate 10Mg/1mL Injection

    Drug page: Morphine

    Burn wound dressing with 10mg morphine sulfate

    Also known as: 10mg morphine

  • DrugMorphine Sulfate 20 MG/ML

    Burn wound dressing with 10mg morphine sulfate

    Also known as: 20mg morphine

06

What researchers measure

Primary outcomes

  1. Serum morphine concentration level

    in ng/ml

    Time frame: 1hour following the end of the surgery

  2. Serum morphine concentration level

    in ng/ml

    Time frame: 2 hours following the end of the surgery

  3. Serum morphine concentration level

    in ng/ml

    Time frame: 3 hours following the end of the surgery

  4. Serum morphine concentration level

    in ng/ml

    Time frame: 6 hours following the end of the surgery

Secondary outcomes

  1. Numeric Pain Rating Scale

    (0- no pain, 10- the worst pain)

    Time frame: 1 hour following the end of the surgery

  2. Numeric Pain Rating Scale

    (0- no pain, 10- the worst pain)

    Time frame: 2 hours following the end of the surgery

  3. Numeric Pain Rating Scale

    (0- no pain, 10- the worst pain)

    Time frame: 3 hours following the end of the surgery

  4. Numeric Pain Rating Scale

    (0- no pain, 10- the worst pain)

    Time frame: 6 hours following the end of the surgery

Other outcomes

  1. Dressing morphine concentration

    in mg/ml

    Time frame: end of the surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07923994
Responsible party
Sponsor
First posted
Nov 9, 2026
Start date
Jan 1, 2016
Primary completion
Feb 1, 2018
Completion
Feb 28, 2022
Last update
Nov 9, 2026

Study contacts

Grzegorz Kowalski, Ph.D.
principal investigator · Poznań University of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Morphine

Start the discussion